Order Article Reprints

Brunetti O, Badalamenti G, De Summa S, Calabrese A, Argentiero A, Fucci L, Longo V, Galetta D, Perrotti PMS, Pinto R, et al. Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Cancers. 2019; 11(6):749. https://doi.org/10.3390/cancers11060749

Brunetti, Oronzo, Giuseppe Badalamenti, Simona De Summa, Angela Calabrese, Antonella Argentiero, Livia Fucci, Vito Longo, Domenico Galetta, Pia Maria Soccorsa Perrotti, Rosamaria Pinto, and et al. 2019. "Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy" Cancers 11, no. 6: 749. https://doi.org/10.3390/cancers11060749

Brunetti, O., Badalamenti, G., De Summa, S., Calabrese, A., Argentiero, A., Fucci, L., Longo, V., Galetta, D., Perrotti, P. M. S., Pinto, R., Petriella, D., Danza, K., Tommasi, S., Leonetti, F., & Silvestris, N. (2019). Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Cancers, 11(6), 749. https://doi.org/10.3390/cancers11060749